Interim Report 1 January to 31 March 2021
Financial Summary for the groupKSEK Q1, 2021 Q1, 2020Profit/loss before tax -8 612 -10 197Total assets 62 482 65 012Earnings per share before and after dilution (SEK) -0,15 -0,21Cash and cash equivalents as per period end 47 268 52 877Equity ratio as per period end 93,6% 94,7% Significant events during the first quarter of 2021 · Cyxone reported first Covid-19 patient screened in Phase 2 clinical trial